Predictive Biotech, Inc. Completes Development Of Allograft Stem Cell Liquid Suspension Product

Company Introduces Its Latest Innovation In Regenerative Treatment Solutions

Salt Lake City, UT — (May 16, 2016) – Predictive Technology Group, Inc. (OTC PINK: PRED), announces that its wholly-owned subsidiary, Predictive Biotech, Inc. has finalized the development process of a new allograft stem cell product derived from umbilical cord blood (UCB).

The use of UCB stem cells has gained popularity in medical science owing to their ability to transform into any type of human cells. UCB refers to the blood and tissue that remains in the attached umbilical cord and placenta after childbirth. UCB derived stem cells are considered unique in their applicability in treating many different diseases and disorders including fusion, wound healing, pain management, genetic and hematopoietic disorders.

Eric Olson, President and CEO of Predictive Biotech, Inc., said, “We are very excited to announce that we have completed the development of our latest biologic product. The ‘CoreCell’ liquid suspension product which is rich in proteins and cells is a strong addition to our current regenerative product portfolio.”

Mr. Olson continues, “The new ‘CoreCell’ product added to our allograft portfolio brings together a full selection of regenerative solutions in three core products, UBC, amniotic liquid suspension products, and amniotic membrane. This group of allograft products gives our clinicians the flexibility to choose the optimum solution depending on the patient indication and personal preference.

Predictive Biotech is currently negotiating with several large orthobiologic distributors to launch the product domestically and internationally. The Company is also considering private label opportunities and plans to eventually distribute the product through its own direct sales organization.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of severe and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and acquires proprietary technologies that open windows into the origin of human illness and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to prevent and treat diseases effectively, www.predictivetechnologygroup.com and www.predrx.com.

About Predictive Biotech, Inc.

Predictive Biotech, Inc. is a cellular and regenerative medicine company, focused on the development, processing and distribution of innovative allograft tissues, stem cells and biomaterials for the treatment of serious and debilitating diseases. The company develops and acquires technologies that incorporate the use of genome sequencing with proprietary tissue/stem cell recovery to ensure the highest quality treatment options for its surgeon customers and their patients.

For further information, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and yes@yesinternational.com and info@predicitivetechnologygroup.com.

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

Predictive Technology Group, Inc. (PRED) Finalizes Acquisition of ReNovo Biotech, Inc.

Company Seeks to Expand Its Current Portfolio with ReNovo’s Stem and Tissue Products

Salt Lake City, UT — (April 12, 2016) – Predictive Technology Group, Inc. (OTC PINK: PRED), announces that the Company has completed its acquisition of ReNovo Biotech, Inc., establishing a new wholly-owned subsidiary called Predictive Biotech, Inc.

The acquisition provides PRED access to ReNovo Biotech’s cellular, tissue, biomaterial and regenerative medicine products and product candidates. Also, PRED will gain access to ReNovo’s distribution channels, including access to customers from a recent signing of a private label agreement.  ReNovo has additional private label agreements pending for future implementations.

As part of PRED’s acquisition and restructuring, ReNovo Biotech’s CEO Eric Olson has been appointed as the President of Predictive Biotech, Inc.

Bradley Robinson, CEO of Predictive Technology Group, Inc., said, “We are very excited to announce that we have completed our due diligence, and have now been able to finalize our acquisition of ReNovo Biotech. This acquisition is a significant milestone for PRED and is the first step in our strategy to expand our product portfolio of technologies that are companion treatment solutions to our molecular diagnostic tests and pharmaceuticals. It will quickly help bring our company into revenue and cash flow through the existing distribution channels and private label partnerships. This allows us to begin clinical trials on the treatment of debilitating diseases with allogeneic and autologous stem cell products.”

Mr. Robinson continues, “Eric Olson is a proven President and CEO with over 20 years of experience in a broad range of various stage companies. Mr. Olson has established an outstanding record of verifiable success exceeding revenue, profit and business growth objectives in the rapidly changing medical device, biologics, and molecular diagnostic industries. He has experience in taking companies public and commercializing new technologies. Most recently, Mr. Olson was the President and CEO of Skeletal Kinetics in Cupertino, CA, and before that the President and CEO of Amedica Corporation in Salt Lake City, Utah.”

PRED continues on its commercialization expansion of novel therapeutics both through internal growths and acquisition of complementary diagnostic and therapeutic companies.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of severe and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and acquires proprietary technologies that open windows into the origin of human illness and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to prevent and treat diseases effectively, www.predictivetechnologygroup.com and www.predrx.com.

About ReNovo Biotech, Inc.

ReNovo Biotech, Inc. is a cellular and regenerative medicine company, focused on the development, processing and distribution of innovative allograft tissues, stem cells and biomaterials for the treatment of serious and debilitating diseases. The company develops and acquires technologies that incorporate the use of genome sequencing with proprietary tissue/stem cell recovery to ensure the highest quality treatment options for its surgeon customers and their patients.

For further information contact, Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 yes@yesinternational.com, www.yesinternational.com.

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

Predictive Technology Group, Inc.’s (PRED) Subsidiary Predictive Therapeutics Receives Notice of Allowance from the United States Patent and Trademark Office on Spine Deformity Diagnostic and Bio-Implant

Notice of Allowance Positively impacts Company’s Pipeline of Diagnostic Tests and Companion Treatment Technologies

Salt Lake City, UT — (March 21, 2016) – Predictive Technology Group, Inc. (OTCPINK:PRED), a life sciences technology holding company, announced its subsidiary Predictive Therapeutics received a ‘Notice of Allowance’ from the United States Patent and Trademark Office.  

Mike Schramm, Predictive Therapeutics’ Director of Intellectual Property, said, “We are pleased that the USPTO examiner agreed with the Patent Trial and Appeal Board and issued a ‘Notice of Allowance’ for all twenty pending claims of the ‘105 application. The claims of the ‘105 application build on previously issued US patents 8,123,787 and 8,641,738 to which ‘105 claims priority and further bolster PRED’s Intellectual Property position.”

Bradley Robinson, PRED’s CEO added, “PRED is excited to move forward with its spinal deformity tests and begin development work on companion therapeutics. This allowance is confirmation of our intellectual property strategy relating to the diagnostic tests and companion therapeutic candidates in our R&D pipeline. We are especially pleased to move our spine diagnostics and related therapeutics one step closer to providing surgeons better insights into the exact cause of their patients’ spine issues and ability to determine the best course of care for patients.”

PRED’s subsidiary Predictive Therapeutics strives to provide its surgeon customers with the highest quality predictive diagnostics and treatment solutions that can ultimately benefit their patients.

About Predictive Technology Group, Inc.

 Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of severe and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to prevent effectively and treat diseases.

For further information contact  Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 yes@yesinternational.com, www.yesinternational.com,  www.predictivetechnologygroup.com and/or www.predrx.com.

 Forward-Looking Statements

 To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

Predictive Technology Group, Inc. (PRED) Announces “Letter of Intent” to Acquire ReNovo Biotech, Inc.

Company Seeks to Combine Use of Molecular Diagnostics with Stem Cell Technologies

Salt Lake City, UT – March 02, 2016 – Predictive Technology Group, Inc. (OTCPINK: PRED), through its wholly-owned subsidiary Predictive Therapeutics, Inc., announces that the Company has entered into a “Letter of Intent” to acquire ReNovo Biotech, Inc.

PRED through this acquisition gains access to ReNovo Biotech’s cellular, tissue, biomaterial and regenerative medicine products, R&D, sales/marketing expertise, distribution channels and product candidates. With the execution of this “Letter of Intent,” PRED expects to finalize and sign a definitive agreement after completing due diligence.

Bradley Robinson, CEO, Predictive Therapeutics, said, “We are very excited to announce our letter of intent to acquire ReNovo Biotech. This acquisition is one of the first steps in PRED’s strategy to expand its portfolio of products and technologies that can be used as companion treatment solutions to our molecular diagnostic tests. This will also allow us to begin clinical trials for the treatment of debilitating diseases with allogeneic and autologous stem cell products.”

Eric Olson, ReNovo Biotech’s CEO states, “We are pleased with the potential to be acquired by the publicly traded company, PRED.  Utilizing PRED’s public experience and its umbrella of unique technologies gives ReNovo a multitude of opportunities that might not otherwise exist. Stem cells can be evaluated and assayed, guaranteeing those specific disease markers are NOT present prior to expanding particular cell lines used in ReNovo’s products. We believe that combining the use of molecular diagnostics with stem cell technologies will be a major breakthrough in our understanding of how stem cells are used for clinical applications.”

Predictive Technology Group, Inc., through its wholly owned subsidiary Predictive Therapeutics, Inc., believes that a ReNovo Biotech, Inc. acquisition can bring immediate revenue and cash flow from ReNovo’s distribution channels and private label partnerships.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

About ReNovo Biotech, Inc.

ReNovo Biotech, Inc. a cellular and regenerative medicine company is focused on the development, processing and distribution of innovative allograft tissues, stem cells and biomaterials for the treatment of serious and debilitating diseases. The company develops and acquires technologies that incorporate the use of genome sequencing with proprietary tissue/stem cell recovery to ensure the highest quality treatment options for its surgeon customers and their patients.

For further information about this release, contact Mr. Rich Kaiser, YES INTERNATIONAL, 757-306-6090 and/or yes@yesinternational.com, www.predictivetechnologygroup.com and/or www.predrx.com

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks the Company may identify from time to time in the future.

PREDICTIVE TECHNOLOGY GROUP, INC. (PRED) ACQUIRES REMAINING OUTSTANDING STAKE IN PREDICTIVE THERAPEUTICS, LLC.

Salt Lake City, UT- Predictive Technology Group, Inc. (PRED.OTCPINK) announces that it acquired the remaining minority position in Predictive Therapeutics, LLC.  In March 2015, the Company acquired a majority stake, 84% control, in what is now the Company’s subsidiary, Predictive Therapeutics, LLC.

A 16% minority stake has been acquired, and the Company has full 100% control of its subsidiary, Predictive Therapeutics, LLC.

Brad Robinson, President, Predictive Technology Group, Inc. states, “Even though PRED controlled the subsidiary since March 2015, the acquisition of the remaining 16% gives us full control and provides ease for accounting purposes.”

The website, www.predrx.com, contains information about PRED’s subsidiary, Predictive Therapeutics, LLC’s business of revolutionizing patient care through novel gene-based companion diagnostics and therapeutics.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

For further information about this release, contact, Mr. Rich Kaiser, YES INTERNATIONAL, 757-306-3090, yes@yesinternational.com and/or www.predrx.com and/or www.predictivetechnologygroup.com. 

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

Predictive Technology Group, Inc.’s (PRED) Subsidiary Predictive Therapeutics Receives Favorable Ruling from the United States Patent and Trademark Office’s Patent Trial and Appeal Board on Spine Deformity Test and Bio-Implant

Decision may positively impact Company’s pipeline tests and companion treatment technologies

Salt Lake City, UT — (February 02, 2016) – Predictive Technology Group, Inc. (OTC PINK:PRED), a life sciences technology holding company, announced its subsidiary Predictive Therapeutics received a favorable ruling from the United States Patent and Trademark Office’s Patent Trial and Appeal Board (“PTAB”) on its spinal deformity molecular diagnostic tests and companion therapeutics (US Patent application 20150127105).

Mike Schramm, Predictive Therapeutics’ Director of Intellectual Property, said, “We are pleased that the Patent Trial and Appeal Board completely reversed the examiner and tacitly approved all twenty pending claims of the ‘105 application and we now look forward to a speedy allowance.  The claims of the ‘105 application build on previously issued US patents 8,123,787 and 8,641,738 to which ‘105 claims priority and further bolster PRED’s Intellectual Property position.”

Bradley Robinson, PRED’s CEO added, “PRED is excited to move forward with the release of the subsidiary’s, Predictive Therapeutics, spinal deformity tests and begin development work on the companion therapeutics. Predictive Therapeutics is committed to providing our surgeon customers with the highest quality predictive diagnostics and treatment solutions that can ultimately benefit their patients.”

The Company believes that this favorable PTAB decision will have an impact on the other diagnostic tests and companion product candidates that are in our R&D pipeline.

About Predictive Technology Group, Inc.

 Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions. PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

For further information about this release, contact, Mr. Rich Kaiser, YES INTERNATIONAL 757-306-6090, yes@yesinternational.com and/or www.predrx.com and/or www.predictivetechnologygroup.com.

 Forward-Looking Statements

 To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

 

PREDICTIVE TECHNOLOGY GROUP, INC. (PRED) MOVES CORPORATE OFFICES TO SALT LAKE CITY, UTAH

Salt Lake City, UT- Predictive Technology Group, Inc. (PRED.OTC), a life sciences technology holding Company, announces moving its Corporate office to Salt Lake City, Utah.

The Corporation’s new address is:

Predictive Technology Group, Inc. 

2749 Parleys Way, Suite 101,Salt Lake City, Utah 84109

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions.  PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

For further information about this release, contact Mr. Rich Kaiser, YES INTERNATIONAL, 757-306-6090 and/or yes@yesinternational.com, www.predictivetechnologygroup.com and/or www.predrx.com.

Forward-Looking Statements 
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

 

PREDICTIVE TECHNOLOGY GROUP, INC. (PRED) ANNOUNCES INITIAL MEMBERS OF FINANCIAL ADVISORY BOARD

PREDICTIVE TECHNOLOGY GROUP, INC. (PRED) ANNOUNCES INITIAL MEMBERS OF FINANCIAL ADVISORY BOARD

Salt Lake City, UT- Predictive Technology Group, Inc. (PRED.OTC), a life sciences technology holding Company, announces initial members of its “Financial Advisory Board.”

In conjunction with closing LifeCode Genetics, Inc. acquisition, Predictive Technology Group, Inc. has formed a “Financial Advisory Board.” These initial board members were the early investors/shareholders of LifeCode Genetics, Inc., who now own PRED shares post acquisition.

The three initial Financial Advisory Board members are as follows:

Dr. Gregory A. Prince – Pioneered the prevention of respiratory syncytial virus (RSV) disease in high-risk infants through the use of monoclonal antibody (SynagisÒ is currently marketed through a partnership between MedImmune and Abbvie); DDS and PhD (pathology) at UCLA; post-doctoral fellowship at the National Institutes of Health; CEO Virion Systems; National Advisory Councils, Johns Hopkins University School of Education, Utah Valley University, Dixie State University (chair); author of over 150 scientific publications in the field of infectious diseases.

Ronald Barhorst – Retired President and CEO of ING Financial Advisers, LLC, Systematized Benefits Administrators, Inc., and ING Investment Advisors, LLC. Mr. Barhorst served as a director of ING Life Insurance Holding Company, Inc. and as an officer of several other ING companies.  Mr. Barhorst currently serves as Chairman on the California State University Foundation Board of Governors.

Jonas Cedergren – Managing Director, JC Capital.  He was previously Managing Director, Head of European Equity Derivatives, and Head of Northern Europe, Barclays Capital, London, Managing Director and Head of Nordics, Credit Suisse, London and Vice President, Bankers Trust. Previous Board Member of Enter Card Europe.

Bradley Robinson, President, Predictive Technology Group, Inc., states, “The commitment and wealth of experience of the members of the ‘Financial Advisory Board’ will bring valued governance and guidance. As PRED moves forward with commercialization of its diagnostics and therapeutics, in its mission of revolutionizing patient care through novel gene-base companion diagnostics and therapeutics, these ‘Financial Advisory Board’ members will provide support and advice in PRED’s current and future business direction.”

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions.  PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

For further information about this release, contact Mr. Rich Kaiser, YES INTERNATIONAL, 757-306-6090 and/or yes@yesinternational.com, www.predictivetechnologygroup.com and/or www.predrx.com.

Forward-Looking Statements 
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

PREDICTIVE TECHNOLOGY GROUP, INC. (PRED) ANNOUNCES ACQUISITION OF LIFECODE GENETICS, INC.

Virginia Beach, VA- Predictive Technology Group, Inc. (PRED.OTC), a life sciences technology holding Company, announces that it acquired LifeCode Genetics, Inc. (“LifeCode”).  LifeCode, a Nevada corporation established in 2011, develops and commercializes gene-based diagnostics.

LifeCode holds strategic gene-based diagnostic assets, which can assist mothers in having healthier pregnancies and, ultimately, healthier babies.

Bradley Robinson, President, Predictive Technology Group, Inc., states, “This acquisition complements the business strategy at PRED.  We look for novel assets which can improve quality of human life.”

Through an equity transaction, LifeCode is now a fully owned subsidiary of Predictive Technology Group, Inc.

PRED’s mission of revolutionizing patient care through novel gene-based companion diagnostics and therapeutics, continues forward with the acquisition of LifeCode Genetics, Inc.

About Predictive Technology Group, Inc.

Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases’ onsets and progressions.  PRED’s subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person’s risk of disease and therapeutic products designed to effectively prevent and/or treat diseases.

For further information about this release, contact Mr. Rich Kaiser, YES INTERNATIONAL, 757-306-6090 and/or yes@yesinternational.com, www.predictivetechnologygroup.com and/or www.predrx.com.

Forward-Looking Statements 
To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

Predictive Technology Group, Inc. (PRED) Announces Issuance of US Patent for Endometriosis Treatment

Virginia Beach,  VA – November 17, 2015- Predictive Technology Group, Inc. (OTCPINKS: PRED), a biotechnology company focused on personalized patient care through novel gene-based companion diagnostics and therapeutics, announces that the United States Patent and Trademark Office has issued US Patent 9,149,499 covering Progesterone/Progestin/Cannabis Therapeutic and Method of Use for the treatment of endometriosis.  Predictive Therapeutics, LLC, a subsidiary of PRED, has exclusive rights to the patent.

About Endometriosis

According to the “The World Endometriosis Research Foundation,” endometriosis affects an estimated 1 in 10 women during their reproductive years (i.e., usually between the ages of 15 to 49).    Endometriosis is a condition where tissue, called endometrium, which lines the uterus is found outside the uterus inducing a chronic inflammatory reaction that may result in scar tissue. Endometriosis affects an estimated 176 million women worldwide regardless of their ethnic and social background. Many remain undiagnosed and are therefore not treated (http://endometriosisfoundation.org/Facts-about-endometriosis.pdf).
About Predictive Therapeutics

Predictive Technology Group, Inc. (“PRED”) is a life sciences holding company.  Predictive Therapeutics, LLC (“PRx”), a subsidiary of PRED, is focused on novel therapeutics leveraged by proprietary gene-based companion diagnostics that provide for the delivery of the most appropriate personalized patient care for the treatment of serious, chronic and debilitating diseases, www.predrx.com and www.predictivetechnologygroup.com.

For further information contact, Rich Kaiser, Investor Relations, YES INTERNATIONAL, 757-306-6090 and/or yes@yesinternational.com

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.